Pharma BD Deal Intelligence
On 2026-09-21 DRI Healthcare Trust announced purchase agreements to acquire certain royalty participation rights in U.S. net sales of tavapadon from funds managed by Bain Capital and NovaQuest Capital Management for an aggregate purchase price of US$316 million. Post-closing DRI receives combined tiered royalties at mid-single-digit to low-double-digit rates on annual U.S. net sales, four annual fixed payments of US$23.4 million on the first four anniversaries of FDA approval, and sales milestones, subject to a hard cap of US$437.5 million in aggregate receipts. Closing is conditioned on FDA approval of tavapadon and other customary conditions. Tavapadon is a selective dopamine D1/D5 receptor partial agonist for the motor symptoms of Parkinson's disease. NOTE: ingested at pending_review by bd-enrichment-2026-10-05.
← Browse all deals · How we score deals
More: 2026 deals